ACELYRIN (SLRN, $4.88) was a top loser over the last three months, falling -1 to $4.88 per share. A.I.dvisor analyzed 920 stocks in the Biotechnology Industry for the 3-month period ending April 18, 2024, and found that of them (5) exhibited an Uptrend while of them (4) demonstrated a Downtrend.